BUZZ-Australia's Noxopharm hits two-week high on autoimmune clinical trial progress
Reuters
Dec 03, 2025
BUZZ-Australia's Noxopharm hits two-week high on autoimmune clinical trial progress
** Shares of Australia's Noxopharm NOX.AX rise 2.1% to A$0.099, their highest level since November 17
** The biotechnology company says the first multiple-dose cohort in the in-human trial for co's autoimmune diseases drug, SOF-SKN, has been successfully completed, bringing co to the final second and final stage of the trial
** Safety Steering Committee has determined the treatment to be safe and well tolerated, with no clinically relevant issues found, co adds
** Stock up 6.5%, YTD
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.